Accumulation of Pro-Cancer Cytokines in the Plasma Fraction of Stored Packed Red Cells

详细信息    查看全文

• 作者：Douglas D. Benson (1) (2)
  Adam W. Beck (3)
  Marie S. Burdine (3)
  Rolf Brekken (3)
  Christopher C. Silliman (2) (4)
  Carlton C. Barnett Jr (1) (2) (4)
  
• 关键词：Transfusion ; Cancer ; Storage lesion ; Cytokines
• 刊名：Journal of Gastrointestinal Surgery
• 出版年：2012
• 出版时间：March 2012
• 年：2012
• 卷：16
• 期：3
• 页码：460-468
• 全文大小：400KB
• 参考文献：1. Yeh JJ, Gonen M, Tomlinson JS, Indrees K, Brennan MF, Fong Y. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumor of the pancreas. Br J Surg. 2007;94:466-72. CrossRef
  2. Park SJ, Kim SW, Jang JY, Lee KU, Park YH. Intraoperative transfusions: Is it a real prognostic factor of periampullary cancer following pancreatoduodenectomy? World J Surg. 2002;26:487-92. CrossRef
  3. Blumberg N, Heal J, Chuang C, Murphy P, Agarwal M. Further evidence supporting a cause and effect relationship between blood transfusion and earlier cancer recurrence. Ann Surg. 1988;207:410-15. CrossRef
  4. Marsh J, Donnan PT, Hamer-Hodges DW. Association between transfusion with plasma and the recurrence of colorectal carcinoma. Br J Surg. 1990;77:623-26. CrossRef
  5. Wobbes T, Joosen KH, Kuypers HH, Beerthuizen GI, Theeuwes GM. The effect of packed cells and whole blood transfusions on survival after curative resection for colorectal carcinoma. Dis Col Rect. 1989;32:743-48. CrossRef
  6. Blajchman MA. The clinical benefits of leukoreduction of blood products. J Trauma. 2006;60:S83-S90. CrossRef
  7. Benson D, Barnett CC Jr. Perioperative blood transfusions promote pancreas cancer progression. J Surg Res. 2011;166:275-79. CrossRef
  8. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): An update. Blood Rev. 2007;21:327-48. CrossRef
  9. Barnett CC Jr, Beck AW, Holloway SE, Kehler M, Schluterman MK, Brekken RA, Fleming JB, Silliman CC. Intravenous delivery of the plasma fraction of stored packed red cells promotes pancreatic cancer growth in immunocompetent mice. Cancer. 2010;116:3862-874. CrossRef
  10. Benson DD, Kelher MR, Meng X, Fullerton DA, Lee JH, Silliman CC, Barnett CC Jr. Gender-specific transfusion affects tumor-associated neutrophil: macrophage rations in murine pancreatic adenocarcinoma. J Gastrointest Surg. 2010;14:1560-565. CrossRef
  11. Moore PK, Benson D, Kelher M, Moore EE, Fragoso M, Silliman CC, Barnett CC Jr. The plasma fraction of stored erythrocytes augments pancreas cancer metastasis in male versus female mice. J Surg Res. 2010;164:23-7. CrossRef
  12. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105:2266-273. blood-2004-07-2929">CrossRef
  13. Moore FA, Moore EE, Sauaia A. Blood transfusion: An independent risk factor for postinjury multiple organ failure. Arch Surg. 1997;132:620-25. CrossRef
  14. Sillman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, Podlosky L, Clarke G, Ambruso DR. Transfusion-related acute lung injury: Epidemiology and a prospective analysis of etiologic factors. Blood. 2003;101:454-62. blood-2002-03-0958">CrossRef
  15. Biffl WL, Moore EE, Offner PJ, Ciesla DJ, Gonzalez RJ, Sillman CC. Plasma from aged stored red blood cells delays neutrophil apoptosis and primes cytotoxicity: Abrogation by poststorage washing but not prestorage leukoreduction. / J Trauma. 2001;50:426-32. CrossRef
  16. Silliman CC, Voelkel NF, Allard JD, Elzi DJ, Tuder RM, Johnson JL, Ambruso DR. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest. 1998;101:1458-467. CrossRef
  17. Silliman CC, Clay KL, Thurman GW, Johnson CA, Ambruso DR. Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med. 1994;124:684-94.
  18. Offner PJ, Moore EE, Biffl WL, Johnson JL, Sillman CC. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg. 2002;137:711-17. CrossRef
  19. Romano G, Mastroianni C, Bancone C, Della Corte A, Galdieri N, Nappi G, De Santo LS. Leukoreduction program for red cell transfusions in cardiac surgery: association with reduced acute kidney injury and in-hospital mortality. J Thorac Cardiovasc Surg. 2010;140:188-95. CrossRef
  20. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994;84:1703-721.
  21. Vamvakas EC, Blajchman MA. Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogenic blood transfusion. Transfus Med Rev. 2000;14:23-3. CrossRef
  22. Bilgin YM, Brand A. Transfusion-related immunomodulation: a second hit in an inflammatory cascade? Vox Sang. 2008;95:261-71. CrossRef
  23. Houbiers JG, Brand A, van de Watering LM, Hermans J, Verwey PJ, Bijnen AB, Pahlplatz P, Eeftinck Schattenkerk M, Wobbes T, de Vries JE. Randomized control trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet. 1994;344:573-78. CrossRef
  24. Van de Watering LM, Brand A, Houbiers JG, Klein-Kranenberg WM, Hermans J, van de Velde C, Cancer Recurrance and Blood transfusion study group. Perioperative blood transfusions, with or without allogenic leukocytes, relate to survival, not to cancer recurrence. Br J Surg. 2001;88:261-66. CrossRef
  25. Technical Manual. American Association of Blood Banks, Bethesda. 2003.
  26. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-67. CrossRef
  27. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-8. CrossRef
  28. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol. 2002;196:254-65. CrossRef
  29. Nozawa H, Chui C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA. 2006;103:12493-2498. CrossRef
  30. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62:1093-102.
  31. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 2001;7:285-89.
  32. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Trejo-Leider L, Leibovich-Rivkin T, Weitzenfield P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A. Inflammatory mediators in breast cancer: Coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011;11:130 doi:10.1186/1471-2407-11-130 . CrossRef
  33. ShimoyamaS, Gansauge F, Gansauge S, Negri G, Oohara T, Beger HG. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res. 1996;56:2703-706.
  34. Fang S, Repo H, Joensuu H, Orpana A, Salven P. High serum angiogenin at diagnosis predicts for failure on long-term treatment response and for poor overall survival in non-Hodgkin lymphoma. Eur J Cancer. 2011;doi:10.1016/j.ejca.2011.02.018 .
  35. Shi X, Friess H, Kleef J, Ozawa F, Buchler MW. Pancreatic cancer: factors regulating tumor development, maintenance, and metastasis. Pancreatology. 2001;1:517-24. CrossRef
  36. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004;102:37-6. CrossRef
  37. Cao R, Bjorndahl MA, Religa P, Clasper S, Garvin S, Galter D, Meister B, Ikomi F, Tritsaris K, Dissing S, Ohhashi T, Jackson DG, Cao Y. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004;6:333-45. CrossRef
  
• 作者单位：Douglas D. Benson (1) (2)
  Adam W. Beck (3)
  Marie S. Burdine (3)
  Rolf Brekken (3)
  Christopher C. Silliman (2) (4)
  Carlton C. Barnett Jr (1) (2) (4)
  
  1. Denver Health Medical Center, 777 Bannock St., Denver, CO, 80204-0206, USA
  2. Department of Surgery, University of Colorado, Aurora, CO, USA
  3. University of Texas-Southwestern Medical Center, Dallas, TX, USA
  4. Bonfils Blood Center, Denver, CO, USA
  

文摘

Introduction Perioperative blood transfusion has been linked to decreased survival in pancreatic cancer; however, the exact causal mechanism has not been elucidated. Allogeneic transfusions are known to expose patients to foreign cells and lipid mediators. We hypothesize that stored packed red cells (pRBCs) contain pro-cancer cytokines that augment tumor progression. We analyzed the plasma fraction of stored pRBCs for pro-cancer cytokines and evaluated the affect of both storage time and leukocyte reduction on these mediators. Methods Chemiarray?analysis for pro-cancer cytokines was performed on the acellular plasma fraction of stored leukocyte-reduced (LR) and non-leukocyte-reduced (NLR) pRBCs at day?1 (D.1–fresh) and day?42 (D.42–outdate) of storage. Elevated expression of monocyte chemotactic protein-1 (MCP-1), regulated on activation, normal T cell expressed and secreted (RANTES), angiogenin, tumor necrosis factor-alpha (TNF-α), epidermal growth factor (EGF), and platelet-derived growth factor (PDGF) was found. Specific enzyme-linked immunosorbent assay was performed for each of these factors in LR and NLR blood at D.1, day?28, and D.42. Data were analyzed by ANOVA. A p value ?.05 was considered significant; N?≥- per group. Migration assays were performed using inhibitors of EGF (gefitinib) and PDGF (imatinib) on murine pancreatic adenocarcinoma cells (Pan02) exposed to D.1 and D.42 LR and NLR plasma. Proliferation assays were performed on Pan02 cells to test the inhibition of PDGF. Results MCP-1 levels increased with storage time in LR blood, 86.3?±-.3?pg/ml at D.1 vs. 121.2?±-.1?pg/ml at D.42 (p--.007), and NLR blood, 78.2?±-.3?pg/ml at D.1 vs. 647.8?±-20.7?pg/ml at D.42 (p--.02). RANTES levels are lower in LR compared to NLR stored blood, 3.0?±-.9 vs. 15.8?±-.7?pg/ml at D.42 (p-lt;-.001), but similar in D.1 blood, 13.8?±-.8?pg/ml in LR vs. 12.0?±-.6?pg/ml in NLR. Angiogenin levels were different between LR and NLR blood, 0?pg/ml (undetectable) vs. 44.2?±-.7?pg/ml (p-lt;-.001). Storage time did not affect concentration. TNF-α levels were not different between LR and NLR blood, and there was no storage time effect on concentration. EGF and PDGF levels increased with storage time in NLR blood only, 216.4?±-.8?pg/ml at D.1 vs. 1,436.4?±-38.6?pg/ml at D.42 for EGF (p--.001), and 61.6?±-.0?pg/ml at D.1 vs. 76.5?±-.7?pg/ml at D.42 (p--.003) for PDGF. Inhibition of EGF reduced migration in Pan02 cells treated with D.42 NLR blood, 245.9?±-1.2 vs. 164.6?±-0.6 cells/hpf (p-lt;-.001). Inhibition of PDGF had no effect on Pan02 migration and reduced cell proliferation in cells treated with D.42 NLR, 181.1?±-.5% over control vs. 157.5?±-.1% (p-lt;-.001). Conclusion Pro-cancer cytokines that can augment tumor progression were identified in pRBCs. Some of these factors are present in fresh blood. The soluble factors identified herein may represent possible therapeutic targets to offset negative effects of transfusion. These data stress the need for efforts in cancer patients to reduce transfusion requirements if needed.